跳至主要内容
临床试验/NCT05057975
NCT05057975已完成不适用

Validation d'Une Solution Digitale intégrée (SUNrise®) d'Analyse Automatique Des Mouvements Mandibulaires Par Intelligence Artificielle Versus Polysomnographie Pour le Diagnostic du Syndrome d'Apnées Obstructives du Sommeil

Sunrise38 个研究点 分布在 1 个国家目标入组 848 人开始时间: 2021年10月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Sunrise
入组人数
848
试验地点
38
主要终点
Time to treatment

研究概览

简要总结

Validation of an integrated digital solution (SUNrise®) of mandibular movement automatic analysis by artificial intelligence versus polysomnography for obstructive sleep apnea diagnosis: a prospective, randomized, parallel-arm, open-label, multicenter, national, controlled study.

详细描述

The new Sunrise integrated digital solution is a disposable 3 gram sensor that sits on the chin for sleep disorders diagnosis. This device records mandibular movements, head movements and position during sleep. Data acquisition is done through a mobile application installed on the user smartphone. Data is then transferred automatically at the end of the test (overnight) to a cloud platform where it is automatically analyzed. The Health Care Professional (HCP) and the patient have access to sleep parameters and report.

The objective of this trial is to determine the place of the Sunrise device in the care pathway in France for patients suspected of having OSA. The assumption is that Sunrise is both non-inferior to the normal practice (i.e., the PSG) on sleepiness at 3 months post-diagnosis, and superior to the PSG (outpatient or in-lab) in terms of time between inclusion and diagnosis appointment and treatment initiation. By speeding up the treatment initiation, the hypothesis is that Sunrise is also superior to the PSG on sleepiness as well as quality of life and work productivity at 3 months post-inclusion. Another assumption is that Sunrise is non-inferior to the PSG on CPAP compliance at 3 months following treatment initiation.

The SUNSAS study will be launched in 19 centers (public and private) in France and will include 848 patients aged 18 to 80 years. Eligible patients will be included and randomized in 2 arms, i.e., the Sunrise arm and the PSG arm. An appointment to discuss the diagnosis and treatment options (for patients suffering from OSA) will be arranged after the procedure (PSG or Sunrise) is performed. On site follow-up visits will be then organized at 3 months post-inclusion and at 3 months post-diagnosis, and a phone call will be scheduled at 3 months post-treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Time to treatment

时间窗: Up to 15 months

To determine the superiority of Sunrise vs PSG in terms of time between inclusion and treatment initiation

Change in daily sleepiness

时间窗: 3 months post inclusion

To determine the superiority of Sunrise vs PSG on sleepiness at 3 months post-inclusion using ESS

Time to diagnosis

时间窗: Up to 12 months

To determine the superiority of Sunrise vs PSG in terms of time between inclusion and diagnosis appointment

次要结局

  • Comparison of Sunrise versus PSG diagnosis(Up to 12 months)
  • cost (€)/QALY(3 months post-diagnosis)
  • Change in work productivity(3 months post-inclusion)
  • Net profit for the French social security(estimated at 3 years)
  • Comparison of CPAP compliance data(3 month after treatment initiation)
  • Difference in the obstructive respiratory disturbance index (ORDI)(Up to 12 months)
  • Change in quality of life(3 months post inclusion visit)

研究者

发起方
Sunrise
申办方类型
Industry
责任方
Sponsor

研究点 (38)

Loading locations...

相似试验

Validation of an Integrated Digital Solution... | 临床试验